Rhenovia Aims To Boost Biosimulation Use In CNS R&D
This article was originally published in Pharmaceutical Approvals Monthly
France's Rhenovia Pharma will recruit talent in the U.S. and Europe and offer its biosimulation techniques for use in developing drugs that target CNS disease, a previously difficult area for computer modeling.
You may also be interested in...
e-Therapeutics Explores Network Pharmacology For Drug Discovery, Moves First Of Its Drugs Into Clinical Studies
The U.K. company e-Therapeutics outlines its novel "network pharmacology" approach for discovery R&D, its product pipeline, and collaboration plans as it moves its first product, with potential in cancer, into Phase I studies.
AstraZeneca is to slash 12% of its workforce in the next three years, as the company forecasts declining revenues in 2012 because of its steep patent cliff, government pricing interventions and R&D pipeline failures.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.